Boehringer attacks French HTA body's downgrading of Pradaxa
This article was originally published in Scrip
Executive Summary
Following a review of the novel oral anticoagulants (NOACs) in the prevention of stroke and systemic embolism, France's health technology assessment body (HAS) has downgraded the "medical benefit" rating (SMR) of Boehringer Ingelheim's Pradaxa (dabigatran etexilate) from "important" to "moderate".